Compare Stocks: IVA, LRMR, and AAPG

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$14.63 +0.5%	$16.71	$14.45 ▼ $37.50	$1.36B	0.12	6,755 shs	1,200 shs
IVA Inventiva	$3.16 -4.8%	$4.21	$3.11 ▼ $7.98	$689.59M	0.79	2.66 million shs	2.79 million shs
LRMR Larimar Therapeutics	$2.67 -1.1%	$3.77	$2.61 ▼ $6.42	$280.48M	0.68	1.46 million shs	867,607 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	+0.55%	-4.75%	-15.91%	-26.74%	-63.63%
IVA Inventiva	-4.82%	-11.24%	-28.99%	-26.51%	-41.04%
LRMR Larimar Therapeutics	-1.11%	-9.80%	-31.01%	-37.62%	-44.61%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$14.63 +0.5%	$16.71	$14.45 ▼ $37.50	$1.36B	0.12	6,755 shs	1,200 shs
IVA Inventiva	$3.16 -4.8%	$4.21	$3.11 ▼ $7.98	$689.59M	0.79	2.66 million shs	2.79 million shs
LRMR Larimar Therapeutics	$2.67 -1.1%	$3.77	$2.61 ▼ $6.42	$280.48M	0.68	1.46 million shs	867,607 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	+0.55%	-4.75%	-15.91%	-26.74%	-63.63%
IVA Inventiva	-4.82%	-11.24%	-28.99%	-26.51%	-41.04%
LRMR Larimar Therapeutics	-1.11%	-9.80%	-31.01%	-37.62%	-44.61%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.18	Buy	$44.75	205.88% Upside
IVA Inventiva	3.00	Buy	$15.86	401.81% Upside
LRMR Larimar Therapeutics	3.00	Buy	$10.33	287.02% Upside

Current Analyst Ratings Breakdown

Latest IVA, LRMR, and AAPG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2026	IVA Inventiva	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
10/8/2026	AAPG Ascentage Pharma Group International	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$46.00 ➝ $33.00
10/2/2026	IVA Inventiva	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$13.00 ➝ $18.00
9/16/2026	IVA Inventiva	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/15/2026	IVA Inventiva	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$11.00 ➝ $14.00
9/14/2026	LRMR Larimar Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$13.00
8/21/2026	AAPG Ascentage Pharma Group International	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$48.00
8/5/2026	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$12.00 ➝ $11.00
7/17/2026	IVA Inventiva	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	LRMR Larimar Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	IVA Inventiva	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$82.10M	16.64	N/A	N/A	$2.04 per share	7.17
IVA Inventiva	$5.07M	129.46	N/A	N/A	($0.22) per share	-14.36
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$0.94 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$177.71M	N/A	N/A	731.50	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	-$400.67M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	-$165.67M	-$1.95	N/A	N/A	N/A	N/A	-137.39%	-97.65%	11/5/2026 (Estimated)

Latest IVA, LRMR, and AAPG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	LRMR Larimar Therapeutics	-$0.35	N/A	N/A	N/A	N/A	N/A
9/28/2026	Q2 2026	IVA Inventiva	-$0.20	-$0.2841	-$0.0841	N/A	$2.88 million	$0.02 million
8/19/2026	H1 2026	AAPG Ascentage Pharma Group International	N/A	-$0.65	N/A	-$0.6450	N/A	$22.24 million
8/14/2026	Q2 2026 TU	IVA Inventiva	N/A	-$0.1450	N/A	-$0.1450	N/A	$0.75 million
8/4/2026	Q2 2026	LRMR Larimar Therapeutics	-$0.3815	-$0.30	+$0.0815	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	1.09	1.22	1.18
IVA Inventiva	0.90	3.81	N/A
LRMR Larimar Therapeutics	N/A	4.70	4.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
IVA Inventiva	19.06%
LRMR Larimar Therapeutics	91.92%

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
IVA Inventiva	32.00%
LRMR Larimar Therapeutics	4.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	767	93.40 million	N/A	N/A
IVA Inventiva	73	207.71 million	141.24 million	Not Optionable
LRMR Larimar Therapeutics	71	103.88 million	99.73 million	Optionable

IVA, LRMR, and AAPG Headlines

Recent News About These Companies

3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead (LRMR)

...

13 minutes ago | marketbeat.com

Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

October 5, 2026 | zacks.com

Larimar Therapeutics Names John Harlow As President And COO

September 30, 2026 | rttnews.com

Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer

September 29, 2026 | globenewswire.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Neogen (NEOG), Larimar Therapeutics (LRMR) and Sagimet Biosciences, Inc. Class A (SGMT)

September 29, 2026 | theglobeandmail.com

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Stock Has Average Price Target of $11.86 According to Brokerages

September 25, 2026 | marketbeat.com

Larimar Therapeutics (NASDAQ:LRMR) Coverage Initiated at Leerink Partners

September 14, 2026 | marketbeat.com

5 Small Drug Stocks Poised to Benefit From a Biotech Recovery

September 14, 2026 | zacks.com

Larimar’s CTI-1601 Study Update Keeps Friedreich’s Ataxia Catalyst in Play

September 3, 2026 | tipranks.com

Larimar’s Phase 3 Friedreich’s Ataxia Trial Puts Nomlabofusp in the Investor Spotlight

August 21, 2026 | tipranks.com

Regulatory and Manufacturing Risks Cloud Larimar Therapeutics’ Accelerated Approval Path for Nomlabofusp

August 7, 2026 | theglobeandmail.com

Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update

August 4, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

July 23, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

July 21, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

July 16, 2026 | prnewswire.com

Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy

July 16, 2026 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

July 14, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

July 9, 2026 | prnewswire.com

Larimar Therapeutics (NASDAQ:LRMR) Director Buys 50,000 Shares

July 9, 2026 | insidertrades.com

LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000

July 8, 2026 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR

July 7, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IVA, LRMR, and AAPG Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$14.63 +0.08 (+0.55%)

Closing price 10/9/2026 03:58 PM Eastern

Extended Trading

$14.63 0.00 (0.00%)

As of 10/9/2026 04:10 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Inventiva NASDAQ:IVA

$3.16 -0.16 (-4.82%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$3.16 +0.00 (+0.06%)

As of 10/9/2026 07:50 PM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Larimar Therapeutics NASDAQ:LRMR

$2.67 -0.03 (-1.11%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.69 +0.02 (+0.60%)

As of 10/9/2026 07:53 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IVA, LRMR, and AAPG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IVA, LRMR, and AAPG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IVA, LRMR, and AAPG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IVA, LRMR, and AAPG Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

Inventiva NASDAQ:IVA

Larimar Therapeutics NASDAQ:LRMR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IVA, LRMR, and AAPG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IVA, LRMR, and AAPG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IVA, LRMR, and AAPG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IVA, LRMR, and AAPG Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

Inventiva NASDAQ:IVA

Larimar Therapeutics NASDAQ:LRMR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools